SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
____________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: JULY 18, 2000
(Date of earliest event reported)
INCYTE GENOMICS, INC.
(FORMERLY INCYTE PHARMACEUTICALS, INC.)
(Exact name of registrant as specified in its charter)
DELAWARE 0-27488 94-3136539
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification
No.)
3160 PORTER DRIVE, PALO ALTO, CALIFORNIA 94304
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 855-0555
<PAGE>
Item 5. Other Events.
-------------
Attached hereto as Exhibit 99.1 and incorporated by reference herein is the
press release dated July 18, 2000 announcing that Incyte's board of directors
have approved a two-for-one stock split in the form of a stock dividend. Incyte
stockholders of record at the close of business on August 7, 2000 will receive
one additional share for each share of common stock held at the time. The
additional shares will be distributed to eligible stockholders on August 31,
2000.
Item 7. Financial Statements and Exhibits.
------------------------------------
(c) Exhibits
99.1 Press release dated July 18, 2000.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: July 18, 2000
INCYTE GENOMICS, INC.
By /s/ John M. Vuko
-------------------
Name: John M. Vuko
Title: Executive Vice President and
Chief Financial Officer
